Source-grounded facts extracted from Sensei Biotherapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sensei Biotherapeutics, Inc. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $150,000,000 (effective 2026-06-18).
“On June 18, 2026, Faeth Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), through or to the Agent (the “ATM Offering”).”
Kristian Humer resigned as Director at Sensei Biotherapeutics, Inc..
“effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.”
Thomas Ricks resigned as Director at Sensei Biotherapeutics, Inc..
“effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.”
Christopher W. Gerry resigned as Director at Sensei Biotherapeutics, Inc..
“effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board.”
Josiah Craver was appointed as Senior Vice President of Finance and principal accounting officer at Sensei Biotherapeutics, Inc..
“Effective as of June 13, 2026, Josiah Craver was ratified as the Company’s Senior Vice President of Finance and appointed as principal accounting officer.”
Brian Stephenson was appointed as Chief Financial Officer at Sensei Biotherapeutics, Inc..
“Effective as of June 13, 2026, Brian Stephenson was appointed as the Company’s Chief Financial Officer and principal financial officer.”
Anand Parikh was appointed as President and Chief Executive Officer at Sensei Biotherapeutics, Inc..
“The Board of Directors (the “Board”) of the Company appointed Anand Parikh as President and Chief Executive Officer of the Company, effective as of June 13, 2026”
Sensei Biotherapeutics, Inc.: Company filed an amendment to its Amended and Restated Certificate of Incorporation to change its name from Sensei Biotherapeutics, Inc. to Faeth Therapeutics, Inc (effective 2026-06-15).
“On June 15, 2026, the Company filed with the Secretary of State of the State of Delaware an amendment to its Amended and Restated Certificate of Incorporation to change the name of the Company from "Sensei Biotherapeutics, Inc." to "Faeth Therapeutics, Inc." (the "Name Change Amendment"). The Name Change Amendment became effective immediately upon filing.”
Sensei Biotherapeutics, Inc. terminated Sales Agreement with Jefferies LLC valued at $50,000,000 (effective 2026-06-10).
“Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed, on March 15, 2022, Faeth Therapeutics, Inc., formerly known as Sensei Biotherapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Prior Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company from time to time may offer and sell shares of its common stock through or to the Agent having an aggregate offering price of up to $50 million. On June 10, 2026, the Company delivered written notice to Jefferies to terminate the Prior Sales Agreement, effective immediately, in accordance with the terms of the Prior Sales Agreement.”
Sensei Biotherapeutics, Inc.: Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to increase authorized shares of common stock from 12,500,000 to 300,000,000 (effective 2026-06-10).
“At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Amendment ”) to increase the authorized number of shares of common stock from 12,500,000 to 300,000,000.”
Sensei Biotherapeutics, Inc. shareholders approved Approval of the 2026 ESPP.
“The votes were cast as follows: Votes For Votes Against Abstained 487,784 262,910 14,828 Broker Non-Votes: 311,652 Proposal No. 6 was approved.”
Sensei Biotherapeutics, Inc. shareholders approved Approval of the 2026 Plan.
“The votes were cast as follows: Votes For Votes Against Abstained 484,662 266,010 14,850 Broker Non-Votes: 311,652 Proposal No. 5 was approved.”
Sensei Biotherapeutics, Inc. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of our common stock from 12,500,000 to 300,000,000.
“The votes were cast as follows: Votes For Votes Against Abstained 1,049,853 10,485 16,836 Broker Non-Votes: — Proposal No. 4 was approved.”
Sensei Biotherapeutics, Inc. shareholders approved Approval of the issuance of shares of the Company’s common stock upon conversion of the Company’s Series B Non-Voting Convertible Preferred Stock, which will (a) represent more than 20% of the shares of common stock outstanding and (b) result in the change of control of the Company pursuant to Nasda.
“The votes were cast as follows: Votes For Votes Against Abstained 747,293 3,397 14,832 Broker Non-Votes: 311,652 Proposal No. 3 was approved.”
Sensei Biotherapeutics, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
“The votes were cast as follows: Votes For Votes Against Abstained 1,055,703 3,879 17,592 Proposal No. 2 was approved.”
Sensei Biotherapeutics, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting.
“The votes were cast as follows: Name Votes For Votes Withheld Bob Holmen 741,993 23,529 Kristian Humer 741,275 24,247 Broker Non-Votes: 311,652 All nominees were elected.”
Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $170.2 million, or $131.45 per basic and diluted share.
“On May 15, 2026, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Sensei Biotherapeutics, Inc. reported the full year ended December 31, 2025 results: net income Net loss was $21.1 million, or $(16.72) per basic and diluted share, EPS $(16.72) per basic and diluted share.
“breast cancer, with additional opportunities in ovarian and lung cancer.” Full Year 2025 Financial Results Cash Position: Cash, cash equivalents and marketable securities were $21.2 million as of December 31, 2025 as compared to $41.3 million as of December 31, 2024. Research and Development (R&D) Expenses: R&D expenses were $11.0 million for the year ended December”
Sensei Biotherapeutics, Inc.: Certificate of Designation creating Series B Preferred Stock filed with Delaware Secretary of State (effective 2026-02-17).
“On February 17, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock”
Sensei Biotherapeutics, Inc. entered into Merger Agreement with HoldCo and Faeth valued at Pre-transaction equityholders of Company hold approx. 10.7%; former equityholders of HoldCo and Faet (effective 2026-02-18).
“pre-transaction equityholders of the Company hold approximately 10.7% of the issued and outstanding shares of Common Stock and former equityholders of HoldCo and Faeth hold approximately 89.3% of the issued and outstanding shares of Common Stock, in each case, calculated on a fully-diluted basis using the treasury stock accounting of method and based on the implied equity values of the Company and the Faeth Entities.”
Sensei Biotherapeutics, Inc. completed an acquisition involving Faeth Holdings Therapeutics, Inc. and Faeth Therapeutics, LLC (closed 2026-02-17).
“On February 17, 2026, the Company completed its acquisition of the Faeth Entities.”
Sensei Biotherapeutics, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“July 2, 2025, Sensei Biotherapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that for 10 consecutive business days, from June 17, 2025 to July 1, 2025, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registra”
Sensei Biotherapeutics, Inc.: Filed Certificate of Amendment for a one-for-twenty reverse stock split and reduction of authorized shares from 250,000,000 to 12,500,000 (effective 2025-06-16).
“On June 12, 2025, Sensei Biotherapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a one-for-twenty (1-for-20) reverse stock split (the “Reverse Stock Split”) of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 250,000,000 to 12,500,000 (the “Shares Reduction”).”
Sensei Biotherapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“January 7, 2025 (the “Second Nasdaq Notice”), that the Company’s application to transfer to the Nasdaq Capital Market was approved and the Company is eligible for an additional 180 calendar day period, or until July 7, 2025 (the “Second Compliance Date”), to regain compliance with the minimum bid price requirement. At the opening of business on January 8, 2025, the Company’s common stock will be transferred to the Nasdaq Capital Market, which operates in substantially the same manner as the Nasdaq Global Select Market, where it continues to trade under the symbol “SNSE”. The Company intends to”
Deneen Vojta resigned as Director at Sensei Biotherapeutics, Inc..
“On October 25, 2024, Deneen Vojta, MD notified the Chair of the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) of her decision to resign from the Board, effective December 31, 2024.”
David Gaiero departed as interim principal financial officer and principal accounting officer at Sensei Biotherapeutics, Inc..
“In connection with such appointment, David Gaiero, who was serving as the Company’s principal financial officer and principal accounting officer on an interim basis, ceased serving in such capacities as of the Effective Date.”
Josiah Craver was appointed as principal financial officer and principal accounting officer at Sensei Biotherapeutics, Inc..
“On September 17, 2024, the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed Josiah Craver as the Company’s principal financial officer and principal accounting officer, effective immediately”
Jessie English resigned as Director at Sensei Biotherapeutics, Inc..
“On June 26, 2024, Jessie English, PhD notified the Chair of the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) of her decision to resign from the Board, effective July 1, 2024.”
Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $8.0 million for the quarter ended March 31, 2024.
“Net loss was $8.0 million for the quarter ended March 31, 2024”
Erin Colgan departed as Chief Financial Officer at Sensei Biotherapeutics, Inc..
“On April 11, 2024, Sensei Biotherapeutics, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Erin Colgan, the Company’s former Chief Financial Officer.”
Erin Colgan resigned as Chief Financial Officer at Sensei Biotherapeutics, Inc..
“On March 27, 2024, Erin Colgan notified Sensei Biotherapeutics, Inc. (the “Company”) of her resignation from all positions with the Company, including as Chief Financial Officer. Ms. Colgan’s resignation is voluntary and will be effective April 10, 2024, and was not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Sensei Biotherapeutics, Inc. reported financial results for full year ended December 31, 2023.
“On February 28, 2024, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2023.”
Samuel Broder resigned as Director at Sensei Biotherapeutics, Inc..
“On February 5, 2024, after serving for nearly five years on the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”), Samuel Broder, MD notified the Company of his decision to resign from the Board, effective immediately.”
Sensei Biotherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
“Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.”
Sensei Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“October 17, 2023, Sensei Biotherapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until April 15, 2024, to regain compliance”
Sensei Biotherapeutics, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $9.4 million.
“Net loss was $9.4 million for the quarter ended June 30, 2023, compared to $10.5 million for the quarter ended June 30, 2022.”
Sensei Biotherapeutics, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-07-10 meeting.
“Proposal No. 2 : Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained 16,096,264 571 448,215”
Sensei Biotherapeutics, Inc. shareholders approved Election of three nominees to serve as directors on the Board of Directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified at the 2023-07-10 meeting.
“Proposal No. 1 : Election of three nominees to serve as directors on the Board of Directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes Bob Holmen 12,245,867 2,181,612 2,117,571 Kristian Humer 11,914,421 2,513,058 2,117,571 Deneen Vojta 11,503,426 2,924,053 2,117,571 All nominees were elected.”
Sensei Biotherapeutics, Inc. entered into Purchase Agreement with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the "Apeiron Parties") (effective 2023-05-23).
“On May 23, 2023, Sensei Biotherapeutics, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the “Apeiron Parties”).”
Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $10.2 million.
“Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2023, and provided recent business updates.”
Sensei Biotherapeutics, Inc. reported financial results for the full year ended December 31, 2022.
“On March 28, 2023, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2022.”
Sensei Biotherapeutics, Inc.: Adopted amended and restated bylaws effective December 5, 2022, updating procedural mechanics, disclosures, universal proxy rules, and other conforming changes (effective 2022-12-05).
“On December 5, 2022, in connection with the new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”) and a periodic review of the bylaws of Sensei Biotherapeutics, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), effective immediately.”
Sensei Biotherapeutics, Inc. announced a restructuring with charges of approximately $1.0 million affecting Company (approximately 40% of its workforce).
“On December 5, 2022, the Board of Directors of Sensei Biotherapeutics, Inc. (the “Company”) approved a plan to reduce the Company’s current workforce by approximately 40% to decrease operating expenses. The Company expects the reduction in force to be substantially completed in the first quarter of 2023. As a result, the Company estimates that it will incur a one-time charge of approximately $1.0 million in connection with one-time employee termination costs, including severance and other benefits.”
Robert Pierce was terminated as Chief Research and Development Officer at Sensei Biotherapeutics, Inc..
“On December 7, 2022, the Company notified Robert Pierce, who had been serving as the Company’s Chief Research and Development Officer, that his employment with the Company would terminate, effective December 7, 2022.”
Sensei Biotherapeutics, Inc. reported financial results for third quarter ended September 30, 2022.
“Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights”
William Ringo was appointed as Chair of the Board at Sensei Biotherapeutics, Inc..
“Effective March 8, 2022, the board of directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed William Ringo to serve as Chair of the Board of the Company and as a member of the Company’s compensation committee and nominating and corporate governance committee.”
Kristian Humer was appointed as director at Sensei Biotherapeutics, Inc..
“Effective July 30, 2021, the board of directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed Kristian Humer to serve as a director of the Company and as a member of the Company’s audit committee.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.